Combination therapy of ETP with the aid of siPIK3CA particularly delivered by dual peptide-modified NPs further exerted synergistic cytotoxicity in drug-resistant CD133(+) H69 SCLC cells. This evidence concerns the gene PROM1 and small cell lung carcinoma.